Appeal support
$0 upfront
15–20% of the first year’s estimated covered value, charged only after a successful appeal.
- ✓ Denial and deadline review
- ✓ Plan-criteria research
- ✓ Documentation checklist
- ✓ Appeal preparation and tracking
Specialty-drug appeal support
DoseBridge helps patients challenge GLP-1 and specialty-medication denials with insurer-specific documentation, organized submissions, and deadline tracking.
No upfront appeal fee. We only charge the success fee if coverage is won.
Our standard
Honest assessment
We review the denial and coverage criteria before recommending a paid path forward.
Patient control
You approve submissions, understand the timeline, and can see what information is being used.
Outcome-aligned
The core appeal starts at $0 upfront. A fee applies only when the appeal secures coverage.
Built for the paperwork gap
DoseBridge focuses on the administrative details that often determine whether a medically supported prescription reaches the right reviewer.
We identify the cited reason, appeal route, deadline, plan requirements, and missing evidence. You get a plain-language assessment before work begins.
We coordinate the relevant records and structure the appeal around insurer-specific criteria, prior therapies, clinical context, and the denial language.
We prepare the submission, track the response window, and organize next steps if the plan requests more information or another review level is available.
One focused starting point
A narrow focus lets us learn plan criteria deeply instead of offering generic billing advice. Where appropriate, the same structured approach can support other recurring specialty-drug denials.
$0
upfront for an eligible appeal
Eligibility, fees, and scope are confirmed in writing before you authorize work.
Pricing
Choose a one-time appeal or ongoing coverage monitoring. Exact success fees are agreed before engagement and depend on the annualized value of coverage.
Appeal support
15–20% of the first year’s estimated covered value, charged only after a successful appeal.
Coverage Guardian
Ongoing support for patients maintaining coverage on a recurring specialty medication.
DoseBridge does not provide medical or legal advice and cannot guarantee an insurer’s decision. Your clinician remains responsible for clinical decisions and prescriptions.
A denial is a decision—not the last word